Archive — US — techcrunch
Miraqules will showcase its blood clotting technology at TechCrunch Disrupt 2025
Miraqules, a Bengaluru-based biotech startup, will showcase its innovative blood clotting nanotechnology at TechCrunch Disrupt 2025. Founded by Sabir Hossain, the technology mimics blood clotting proteins and enables rapid bleeding control within minutes. The startup is a Top 20 finalist and has secured multiple patents, aiming for regulatory approval in India and the U.S. soon.
Key points
- Miraqules developed a blood clotting technology using a nanopowder that mimics blood clotting proteins.
- The technology provides quick feedback by stopping bleeding within one to two minutes.
- The startup was founded by Sabir Hossain, who was inspired by a personal incident involving his father.
- Hossain and his team created the product after experimenting with biomaterials during grad school.
- Miraqules has filed 11 patents in various countries, including India and the U.S.
- Their technology is currently being piloted in Indian trauma care centers, with plans for wider deployment.
Why it matters
- The rise of biotechnology startups in India shows a growing trend in innovative healthcare solutions by 2025.
- Advancements in nanotechnology are crucial as they provide rapid medical interventions and have gained traction in emergency care.
- Miraqules' approach of pursuing FDA feedback early emphasizes the importance of regulatory strategy for biotech firms.
Miraqules is poised to revolutionize emergency care with its blood clotting technology, reflecting significant advances in biotechnology and innovation at TechCrunch Disrupt 2025, which is key for startups seeking to address critical healthcare challenges.